Jones Trading Rates Enliven Therapeutics (ELVN) buy

Jones Trading reiterated its Buy rating on Enliven Therapeutics, Inc. (NasdaqGS:ELVN) on June 29, 2026, maintaining a price target of $70. This update comes as the stock traded near $50.08 on Monday.

Other Institutional Activity in Enliven Therapeutics

Polar Capital Holdings PLC increased its stake in Enliven Therapeutics by 1,552,253 shares, ending with 5,065,933 shares valued at about $198.6 million, marking a 44.2% increase. BlackRock, Inc. also added 71,381 shares to its holdings, bringing its total to 3,684,707 shares worth roughly $144.4 million, a 2.0% increase. In contrast, Commodore Capital LP reduced its position by 1,417,809 shares, leaving it with 3,275,000 shares valued at $128.4 million, a 30.2% decrease. FMR LLC trimmed its holdings by 278,389 shares, resulting in 6,829,246 shares valued at about $267.7 million, a 3.9% decrease.

Enliven Therapeutics, Inc. Stock Up 2.6%

Shares of Enliven Therapeutics traded near $50.08 on Monday. The company has a market cap of around $3.58 billion, with a forward P/E ratio of -20.6, indicating it currently isn't profitable. Its beta is 0.396, suggesting lower volatility compared to the market. The stock's 52-week range is between $14.79 and $50.56, with a 50-day moving average of $42.11 and a 200-day moving average of $28.94. Enliven Therapeutics has a strong liquidity position, with a current ratio of 40.32 and a quick ratio of 39.38, and a low debt-to-equity ratio of 0.067.

Insider Buying and Selling at Enliven Therapeutics, Inc.

Recent insider activity at Enliven Therapeutics includes OrbiMed Advisors LLC selling 860,123 shares on June 22, 2026. On June 17, 2026, CFO Benjamin Hohl sold 6,018 shares at an average price of $43.80 under a planned sale and also bought 6,018 shares at $2.48. Chief Medical Officer Helen Louise Collins sold 5,000 shares at an average price of $43.80 under a planned sale and also purchased 5,000 shares at $2.48.

Analysts Set New Price Targets

On June 29, 2026, Jones Trading reiterated its Buy rating on Enliven Therapeutics with a $70 price target. Earlier in June, Stifel initiated coverage with a Buy rating and a $60 target. Mizuho maintained its Buy rating with a $62 target on June 2, 2026. The overall analyst consensus is a Buy, with an average target price of $60.11 based on nine analyst opinions.

About Enliven Therapeutics

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boulder, Colorado. It focuses on developing small molecule inhibitors for cancer treatment. The company is working on ELVN-001, a kinase inhibitor for chronic myeloid leukemia, and ELVN-002, an inhibitor targeting HER2 mutant tumors in non-small cell lung cancer. Founded in 2019, it is led by CEO Samuel S. Kintz and employs 61 people.

Bottom Line

Enliven Therapeutics is drawing attention with its innovative cancer treatments and recent analyst support. While Jones Trading's reiterated Buy rating reflects confidence, investors should remember that these ratings are backward-looking and may not reflect current market conditions.